SoFi CEO enters prepaid forward contract on 1.5 million shares
On Wednesday, BMO Capital Markets maintained a positive outlook on Gilead Sciences stock, reaffirming an Outperform rating and a $115.00 price target. The stance comes in response to reports that the Department of Health and Human Services (HHS) is contemplating significant reductions in funding for domestic HIV prevention efforts. These potential cuts could affect Gilead Sciences, known for its HIV prevention treatments. The company, with a market capitalization of $132 billion and impressive year-to-date returns of 20%, has shown strong financial health according to InvestingPro analysis, which rates the company’s overall financial condition as "GOOD."
The Wall Street Journal recently reported that HHS is considering major funding cuts, which could include slashing the Centers for Disease Control and Prevention’s (CDC) budget by approximately $1.3 billion, as it was in 2023. Gilead Sciences, whose PrEP (pre-exposure prophylaxis) medications are a cornerstone of HIV prevention, could face challenges if these changes are implemented. InvestingPro data shows the company maintains a strong position with a gross profit margin of 78% and sufficient cash flows to cover its obligations, suggesting resilience against potential headwinds.
Despite the potential reduction in HIV prevention funding, BMO Capital analysts believe that the impact on Gilead’s PrEP franchise will be modest. They note that while the news may pose a headline risk to the company’s shares, it does not spell disaster for its PrEP business.
Investors have been closely monitoring developments in Gilead’s PrEP offerings, especially with the anticipated launch of a new long-acting PrEP medication, lenacapavir, expected in the summer of 2025. The introduction of lenacapavir is poised to be a significant event for the company and those invested in HIV prevention.
Gilead Sciences, listed on (NASDAQ:GILD), continues to focus on advancing treatments in the HIV sector, with BMO Capital expressing confidence in the company’s ability to navigate potential headwinds from policy changes.
In other recent news, Gilead Sciences has presented notable developments in its financial and operational activities. The company showcased promising results from its HIV treatment portfolio at the 2025 Conference on Retroviruses and Opportunistic Infections, highlighting the efficacy of Biktarvy in treating HIV and HBV co-infections and advancements in its investigational drug lenacapavir for HIV prevention. Concurrently, Gilead Sciences announced the departure of its Senior Vice President, Corporate Controller, and Chief Accounting Officer, Sandra Patterson, with Diane E. Wilfong stepping in as interim replacement.
Additionally, analysts from Bernstein have reiterated their Outperform rating for Gilead Sciences, maintaining a price target of $120.00. The firm cited high expectations for the company’s preventative HIV treatment, Len for PrEP, and its potential market impact. Meanwhile, Gilead faces potential challenges as reports suggest the Health and Human Services Department may reduce federal funding for domestic HIV prevention efforts, which could impact companies like Gilead involved in this sector.
Furthermore, the company reported progress in a Phase 1 study for once-yearly formulations of lenacapavir, showing promising results for HIV prevention. These updates reflect Gilead’s ongoing efforts and challenges in the biopharmaceutical landscape, with a focus on innovation and market expansion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.